The expanding use of speech biomarkers as drug development tools has allowed researchers to better understand the symptoms and disease progression of patients with dementia. The use of acoustic, linguistic, and content analysis can assist with diagnosis and may discriminate between forms of dementia. At this year's Alzheimer’s Association International Conference annual meeting Winterlight presented new data on how speech biomarkers can be used in clinical research. In this webinar, Jessica Robin, PhD, Director of Clinical Research at Winterlight Labs, and Jed Meltzer, PhD, Neurorehabilitation Scientist at Rotman Research Institute, will discuss:
- How to use open-ended speech tasks, such as clinical interviews, to determine cognition and function.
- How to measure executive function using objective, speech-based biomarkers.
- How to discriminate between Alzheimer’s Disease, Frontotemporal dementia, and Parkinson’s dementia using speech biomarkers.
- Updates on how voice and speech biomarkers are being used in intervention studies of new treatments for dementia.